The U.S. International Trade Commission (ITC) has formally opposed Apple’s motion to temporarily lift the ban for the duration of its appeal, concerning the Apple Watch Series 9 and the second-generation Apple Watch Ultra. This motion was in response to a temporary sales halt in December, stemming from an ongoing patent infringement dispute over blood oxygen sensing technology.
Masimo, a U.S.-based medical technology company, initiated a lawsuit against Apple, accusing the tech giant of infringing on patents related to blood oxygen sensing technology. This feature was first introduced with the Apple Watch Series 6 in 2020, providing users with information about the oxygen levels in their blood, typically ranging between 95% and 100%. Despite a hung jury in the lawsuit, on October 26, the commission found Apple in violation and imposed both a U.S. import ban and a sales injunction.
While the sales ban on the Apple Watch Series 9 and the second-generation Apple Watch Ultra was temporarily lifted at the end of December, the U.S. appeals court is set to decide on January 12 whether to uphold the Apple Watch ban throughout the duration of Apple’s appeal against the initial ITC ruling.
Apple is said to be actively working on software adjustments to address the alleged patent infringement. However, Masimo contends that compliance may require a modification to the Apple Watch’s hardware design.
The post ITC opposes sales ban pause in Apple Watch blood oxygen sensing patent dispute first appeared on The Apple Post.
Original Article Published at The Apple Post
________________________________________________________________________________________________________________________________
